LL-37
Men's HealthMale-physiology practitioners evaluate LL-37 against the HPG axis, androgenic markers, and downstream effects on body composition, libido, and recovery. Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3 Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes.. For men running LL-37 alongside TRT, post-cycle restarts, or fertility-aware protocols, baseline labs (total/free testosterone, LH, FSH, estradiol, prolactin, SHBG) and a 6-8 week follow-up panel are the standard monitoring framework at the 100-500 mcg daily subq for 4-8 weeks dose.
Key Takeaways
Male-physiology lens: LL-37 is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 100-500 mcg daily subq for 4-8 weeks via subq/topical/nebulised; cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Male users' practical questions about LL-37 reduce to: hormonal coherence, TRT integration, and prostate / cardiovascular safety. Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. The mechanism shapes the answer to each. The subsections below work through HPG-axis impact and TRT compatibility before examining the body composition and male-physiology response.
Male body composition and performance response
Male users typically respond to LL-37 on the recovery, lean-mass, or visceral-fat dimension depending on the compound's primary pharmacology. Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. For men whose body composition goals are driven by training, the dose-timing relative to workouts and sleep is often the critical lever rather than the absolute dose itself.
Compatibility with TRT and post-cycle protocols
For men currently on TRT or planning a post-cycle restart, LL-37 is typically compatible because it does not directly engage the HPG axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.
Interaction with the HPG axis
LL-37's relationship to the male HPG axis is one of the central practical questions. Direct receptor-level engagement of the HPG axis is not the principal mechanism, but downstream effects on testosterone, LH/FSH, and prolactin can still occur and warrant baseline and follow-up labs in male users. The practical takeaway is that any male user beginning a course of LL-37 should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.
Testosterone Optimisation in men responds to LL-37 with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
For libido in male users, LL-37 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Where male users target prostate health, LL-37 is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
Hair Loss in men responds to LL-37 with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-500 mcg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 100-500 mcg | Daily SubQ for 4-8 weeks |
| Maintenance phase | SubQ | 70-500 mcg | Ongoing with periodic pauses |
Dose timing for LL-37 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
LL-37 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- LL-37 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with LL-37's mechanism in male physiology protocols.
- LL-37 + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with LL-37's mechanism in male physiology protocols.
- LL-37 + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with LL-37's mechanism in male physiology protocols.
- LL-37 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with LL-37's mechanism in male physiology protocols.
Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions.
Lens-specific safety considerations for male physiology use of LL-37: Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| LL-37 | Cathelicidin antimicrobial peptide | Variable; tissue-localised | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
Is LL-37 compatible with TRT?
Does LL-37 affect hair, prostate, or erythrocyte production?
Best time of day to dose for male users?
How does LL-37 affect the HPG axis?
What is the mechanism of action of LL-37?
What are the safety considerations for LL-37?
Start a LL-37 Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified LL-37 and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- 4493 Da
- Sequence length
- 37 aa
- Half-life
- Variable; tissue-localised
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Preclinical + small human series
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for LL-37 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for LL-37
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised